<DOC>
	<DOCNO>NCT00796315</DOCNO>
	<brief_summary>The primary goal study characterize pharmacokinetics doxylamine succinate child age 2 &lt; 18 year . Once characterize , pediatric pharmacokinetic data pool historical adult PK data study assess whether exist Over-the-Counter ( OTC ) dose provide comparable systemic drug exposure associate efficacy adult .</brief_summary>
	<brief_title>Study Evaluating Pharmacokinetics Doxylamine Succinate Children</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Doxylamine</mesh_term>
	<mesh_term>Doxylamine succinate</mesh_term>
	<criteria>male female child age 2 &lt; 18 year , minimum weight 24 lbs &gt; 5th percentile &lt; 95th percentile weight base age sex , time dose study medication previous diagnosis allergic rhinitis , history frequent upper respiratory infection ( URI ) /common cold either symptomatic , risk future URI , include follow 3 criterion Frequency Criterion : &gt; 6 infection per year child age 2 &lt; 6 year age &gt; 4 infection per year child age 6 &lt; 18 year age Crowding Criterion : 4 person live home 3 person sleep one bedroom Exposure Criterion : another family member home ill URI / common cold child family attend preschool school 6 child group . good general health likely compliant complete study parent ( ) legally authorize representative ( ) likely compliant complete study accord Investigator whose parent ( ) legally authorize representative ( ) sign date Institutional Review Board ( IRB ) approve consent form subject participate study must sign assent form require site 's IRB postmenarchal female , subject must negative urine pregnancy test screening checkin , serum pregnancy test screening , site require ; postmenarchal female , subject must practice abstinence use effective form birth control ( eg , intrauterine device , low dose oral contraceptive [ 50g ethinyl estradiol ] , contraceptive implant injection , diaphragm spermicide , cervical cap , consort use condom ) least 3 month enrol study . history presence follow medical condition : peptic ulcer , pyloroduodenal obstruction gastrointestinal disease ; renal hepatic disease ; diabetes mellitus ; hyperthyroidism ; cardiovascular disease ; increase ocular pressure glaucoma ; endocrine , metabolic , hematologic neoplastic disease ; seizure disorder ; chronic respiratory disease include asthma , emphysema chronic bronchitis ; autoimmune disease ; immunodeficiency tuberculosis ; bladder neck obstruction ; significant dermatologic condition . know sensitivity allergy doxylamine succinate history severe allergic reaction drug multiple food/drug allergy experience febrile illness great 100Â°F within 7 day prior dose report know enzymeinducer , enzymeinhibitor , report chronic exposure enzymeinducers paint solvent pesticide within 30 day prior dose , unless approve Sponsor report prescription drug herbal remedy usage within 14 day prior dose except low dose contraceptive , unless approve Sponsor report nonprescription drug supplemental vitamin usage within 5 day prior dose unwillingness refrain caffeine xanthinecontaining beverage , include coffee tea , alcohol , grapefruit juice , chocolate , Seville oranges 24 hour prior admission throughout study report use tobacco , smoke cessation product , product contain nicotine within 3 month prior Screening acute illness ( except describe Section 3.3.1 Inclusion Criterion b ) within 14 day prior dose ; unless approve Sponsor ; laboratory value outside laboratory reference range consider clinically significant Investigator history diagnosis Hepatitis B , Hepatitis C , human immunodeficiency virus ( HIV ) , thyroid disease history alcohol illicit drug use positive urine drug abuse screen pregnant lactating ( postmenarchal female subject make aware pregnancy test occur study , sexually active must take appropriate step ensure become pregnant study ) make blood donation plasma donation within 4 week prior dose ; participate another investigational drug study protocol within 30 day prior dose ( Day 1 ) history presence , upon clinical evaluation , illness condition might impact safety subject test product administration evaluability drug effect , base Investigator 's discretion unable avoid driving , operate machinery , task require alertness study . unable unwilling avoid contact sport , strenuous exercise ( e.g . weight lift ) , exercise train condition intramuscular injection least 1 week baseline visit creatine phosphokinase ( CPK ) evaluate</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pharmacokinetic study</keyword>
</DOC>